LBI Applied Diagnostics

The LBI:AD aims to develop innovative non-invasive functional imaging markers for highly personalise

The Ludwig Boltzmann Institute Applied Diagnostics (lbi:ad) follows a new dual biomarker concept for tumor diagnosis. The focus of the institute lies on the development of non-invasive diagnostic methods combining molecular epigenetic and genetic signatures with molecular imaging biomarkers for PET and SPECT analysis. The combination of these two methods will allow for improved functional, spatial and temporal assessment of tumor load and molecular tumor characterization.